Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir
- 28 December 2022
- journal article
- research article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 29 (4) , 543.e5-543.e9
Abstract
No abstract availableKeywords
Funding Information
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- French Government Ministry of Education Research and Technology
- Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation
- Ministère des Solidarités et de la Santé
This publication has 13 references indexed in Scilit:
- Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19Open Forum Infectious Diseases, 2022
- Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 SubvariantsNew England Journal of Medicine, 2022
- Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2Journal of Infection, 2022
- Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodiesNature Medicine, 2022
- Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19JAMA, 2022
- Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2New England Journal of Medicine, 2022
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19New England Journal of Medicine, 2022
- Early Remdesivir to Prevent Progression to Severe Covid-19 in OutpatientsNew England Journal of Medicine, 2021
- Quantifying the relationship between SARS-CoV-2 viral load and infectiousnesseLife, 2021
- A living WHO guideline on drugs for covid-19 (2020-2023)BMJ, 2020